Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
From licensing, to clinical trials, to competitor activity – you’ll stay up to date on news worldwide thanks to our global team of 60+ journalists. We go beyond headlines too, with access to key decision-makers and best-in-class proprietary data.
How it works
You’ll get business-critical market and company intelligence from our network of analysts, journalists and key opinion leaders. They cover companies from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and fields including cancer, cardiovascular, diabetes, dermatology, influenza and oncology.
How Scrip can help
Understand what’s behind the headlines – we focus on the strategic implications of global pharma news so you can see what developments mean for your business.
Scrips global team of journalists span key markets around the clock
Get exclusive access to accurate data, timely insights and trusted analysis that delivers to gain competitive advantage
Access interviews with leading decision makers, industry experts and thought leaders, across the industry.
Put your questions about any of our news stories, data and analysis to our expert journalists and analysts.
Scrip
By Jessica Merrill 20 Jun 2017
Every $1 reduction in the average reimbursement for a generic prescription would reduce US healthcare spending by $4bn, according to a study from Brookings.
Topic Policy and regulation
Scrip
By Joseph Haas 20 Jun 2017
A PwC report on medical cost trends projects that while US health care cost-growth has plateaued, several inflationary factors remain.
Scrip
By Sten Stovall 19 Jun 2017
Roche CEO Severin Schwan says analysts at ASCO missed a key APHINITY message on Herceptin follow-on Perjeta.
Topic Research
Scrip
By Emily Hayes 14 Jun 2017
CDK4/6 inhibitors offer impressive progression-free survival data in breast cancer, but lack of overall survival data may mean the class will be relegated to the second-line setting.
Topic Clinical trials
Scrip
By Mike Ward 06 Jun 2017
David Chiswell, Jane Dancer and Konstantinos Efthymiopoulos shared lessons they have learnt over the years about deal making at this year.
Scrip
By Lubna Ahmed 06 Jun 2017
The pharmaceutical industry may have pioneered some great science, but when it comes to digital health it has been behind the curve.
Topic BioPharmaceutical
Scrip
06 Jun 2017
The TRK inhibitor won over ASCO with deep and durable responses across 17 cancer types, but diagnostics will be the true test of the tumor-agnostic approach.
Topic Personalized Medicine
Scrip
By Melanie Senior 06 Jun 2017
Pharma does not need to make wearables. Instead, it needs to figure out how best to use the data that these technologies can provide.
Topic Personalized Medicine
Scrip
By Mary Jo Laffler 30 May 2017
Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer.
Topic Drug approval
Scrip
By Mandy Jackson 30 May 2017
Neurocrine's stock fell 9% on May 24 after the company said a closely-watched Phase II study for Ingrezza in pediatric Tourette's syndrome failed.
Topic Clinical trials
Scrip
By Alex Shimmings 25 May 2017
The Pharmaceutical and Biotech industries’ R&D performance can be measured in a number of ways. View the infographic here.
Topic Research
Scrip
By Mandy Jackson 25 May 2017
Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments.
Topic Business strategies
Scrip
By Lucie Ellis 25 May 2017
Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics.
Topic Biosimilars
Scrip
By Mandy Jackson 22 May 2017
Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago.
Topic Clinical trials
Scrip
By Sten Stovall 22 May 2017
Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.
Topic Business strategies
Scrip
19 Jun 2017
Scrip
19 Jun 2017
Scrip
19 Jun 2017
Scrip
19 Jun 2017
Scrip
19 Jun 2017
Scrip
19 Jun 2017
Scrip
19 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Scrip
16 Jun 2017
Denise specializes in
+26 year(s) experience
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions. Its accurate and objective drug sales forecasts and segmented patient based disease forecasts are continually updated in reaction to key changes in the market, ensuring decisions are always based on the current reality of the market place.
Medtrack follows all the companies and people that touch Healthcare: financing, drug discovery, manufacturing, contract manufacturing and development. Coverage spans discovery through patent expiry and loss of market exclusivity and generic entry.
Trialtrove has the depth and breadth you need to see the complete view of the global clinical trial landscape and easily track your competitors' clinical R&D activity. The insight added to trials, and the continual monitoring of trial activity make this your best source for protocol design comparison to results readouts.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
